Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for cemiplimab

  1. Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)

    Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA802

  2. Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)

    NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    20 June 2023

    Sections for TA901

  3. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]

    In development [GID-TA10907] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  4. Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA848)

    NICE is unable to make a recommendation on cemiplimab (Libtayo) for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. This is because Sanofi did not provide an evidence submission.

    Technology appraisal guidance
    Published
    1 December 2022

    Sections for TA848

  5. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development [GID-TA10900] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA802.

    Technology appraisal guidance
    Published
    7 August 2019